Several key factors mean that we're unlikely to face a major COVID-19 surge this winter, argue Dr. Michael Daignault (MichaelDaignau3) and Dr. Monica Gandhi (MonicaGandhi9)
in both countries have received the updated booster. BQ.1.1 became dominant in France at the end of October but has not led to a surge in hospitalizations or ICU admissions.
So, a convergence of rapidly accruing mutations demonstrating immune evasiveness in the lab has not generated a surge in infections or hospitalizations in the real world. This certainly begs the question: has SARS-COV-2 hit an evolutionary ceiling in the face of our high population immunity?We rarely encounter patients with severe COVID in the ED or hospital wards now, in sharp contrast to the winter of 2020.
The majority of states and county public health departments still do not delineate COVID-19 hospitalizations between those admitted primarily for COVID vs. those who incidentally test positive. The CDC in fact in September. But many hospitals and health care systems have been reluctant to relinquish this outdated practice. As such, given the ability of BQ.1 and BQ.1.
In fact, since the advent of Omicron, multiple studies have demonstrated that Omicron is just not very good at infecting lung tissue. As early as January 2022, we hadshowing that Omicron had an affinity for replicating rapidly in the upper airways but markedly less tropism for alveolar lung cells.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
What is the prevalence of COVID-19 detection by PCR among deceased individuals in Lusaka, Zambia? A postmortem surveillance studyObjectives To determine the prevalence of COVID-19 postmortem setting in Lusaka, Zambia. Design A systematic, postmortem prevalence study. Setting A busy, inner-city morgue in Lusaka. Participants We sampled a random subset of all decedents who transited the University Teaching Hospital morgue. We sampled the posterior nasopharynx of decedents using quantitative PCR. Prevalence was weighted to account for age-specific enrolment strategies. Interventions Not applicable—this was an observational study. Primary outcomes Prevalence of COVID-19 detections by PCR. Results were stratified by setting (facility vs community deaths), age, demographics and geography and time. Secondary outcomes Shifts in viral variants; causal inferences based on cycle threshold values and other features; antemortem testing rates. Results From 1118 decedents enrolled between January and June 2021, COVID-19 was detected among 32.0% (358/1116). Roughly four COVID-19+ community deaths occurred for every facility death. Antemortem testing occurred for 52.6% (302/574) of facility deaths but only 1.8% (10/544) of community deaths and overall, only ~10% of COVID-19+ deaths were identified in life. During peak transmission periods, COVID-19 was detected in ~90% of all deaths. We observed three waves of transmission that peaked in July 2020, January 2021 and ~June 2021: the AE.1 lineage and the Beta and Delta variants, respectively. PCR signals were strongest among those whose deaths were deemed ‘probably due to COVID-19’, and weakest among children, with an age-dependent increase in PCR signal intensity. Conclusions COVID-19 was common among deceased individuals in Lusaka. Antemortem testing was rarely done, and almost never for community deaths. Suspicion that COVID-19 was the cause of deaths was highest for those with a respiratory syndrome and lowest for individuals |19 years. Data are available upon reasonable request.
Consulte Mais informação »
Nasal COVID-19 vaccine approved for use as booster in IndiaA nasal COVID-19 vaccine based on technology licensed from Washington University in St. Louis has been approved for emergency use in India as a booster for people who have already received two doses of other COVID-19 vaccines. The approval follows the Indian government's emergency use authorization in September of the vaccine as a primary series of two doses, and makes the intranasal vaccine the world's first to receive approval as both a primary vaccine for COVID-19 and a booster.
Consulte Mais informação »
Zero to sickly? China’s covid climbdownWith astonishing speed, the machinery of testing, tracing and lockdowns is being dismantled. We examine the risks that will pose to a country that is not prepared for big outbreaks. A winemaker’s lawsuit in Napa Valley reveals why many Californians believe regulators are unfriendly to business. And a clever solution to spare sharks from becoming unwanted “bycatch”. Help us make the show better: take our listener survey at http://economist.com/intelligencesurvey For full access to print, digital and audio editions of The Economist, subscribe here www.economist.com/intelligenceoffer Hosted on Acast. See acast.com/privacy for more information.
Consulte Mais informação »
Lancashire school closures today as snow, ice and Covid takes tollParklands High School in Chorley is fully closed while Bleasdale School in Carnforth is partially shut
Consulte Mais informação »
Notts firm enters administration with nearly 30 jobs lostThe company has been affected by the Covid pandemic and Ukraine war
Consulte Mais informação »
Bioengineered soluble ACE2 for brain protection against SARS-CoV-2 infectionBioengineered soluble ACE2 for brain protection against SARS-CoV-2 infection biorxivpreprint NorthwesternU ChariteBerlin UChicago brain SARSCoV2 ACE2 COVID19 coronavirus covid
Consulte Mais informação »